CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery
<p>Abstract</p> <p>Background</p> <p>There is no consensus regarding the management of ovarian cancer patients, who have shown complete clinical response (CCR) to primary therapy and have rising cancer antigen CA-125 levels but have no symptoms of recurrent disease. The...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2013-02-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://www.ovarianresearch.com/content/6/1/14 |